These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38748388)

  • 1. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A; Whichello C; Le HH; Kern DM; Fernandez GS; Turner V; Das A; Quaife M; Ross AP
    Patient; 2024 May; ():. PubMed ID: 38748388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
    Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
    Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
    Yang S; Li X; Wang J; Wang T; Xu Z; Gao H; Chen G
    Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
    Roy R; Alotaibi AA; Freedman MS
    CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
    Chun J; Giovannoni G; Hunter SF
    Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
    Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
    Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
    Baker D; Forte E; Pryce G; Kang AS; James LK; Giovannoni G; Schmierer K
    Mult Scler Relat Disord; 2023 Jan; 69():104425. PubMed ID: 36470168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.
    Yang X; Yan Y; Liu S; Wang Z; Feng X
    Front Pharmacol; 2024; 15():1376494. PubMed ID: 38846098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
    Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
    Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
    Chaudhry BZ; Cohen JA; Conway DS
    Neurotherapeutics; 2017 Oct; 14(4):859-873. PubMed ID: 28812220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ponesimod for the treatment of relapsing multiple sclerosis.
    Baldin E; Lugaresi A
    Expert Opin Pharmacother; 2020 Nov; 21(16):1955-1964. PubMed ID: 32808832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
    Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    McGinley MP; Cohen JA
    Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review.
    Constantinescu V; Haase R; Akgün K; Ziemssen T
    Ther Adv Neurol Disord; 2022; 15():17562864221133163. PubMed ID: 36437849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more.
    Constantinescu V; Akgün K; Ziemssen T
    Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):675-693. PubMed ID: 36260948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
    Sriwastava S; Chaudhary D; Srivastava S; Beard K; Bai X; Wen S; Khalid SH; Lisak RP
    J Neurol; 2022 Mar; 269(3):1678-1687. PubMed ID: 34800168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients.
    Sharma K; Chaudhary D; Beard K; Srivastava S; Khalid SH; Sriwastava S
    Mult Scler Relat Disord; 2022 Mar; 59():103675. PubMed ID: 35168095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P
    Kihara Y; Jonnalagadda D; Zhu Y; Ray M; Ngo T; Palmer C; Rivera R; Chun J
    FASEB J; 2022 Feb; 36(2):e22132. PubMed ID: 34986275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
    Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G
    Front Immunol; 2024; 15():1416133. PubMed ID: 38911847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article.
    Cohan S; Lucassen E; Smoot K; Brink J; Chen C
    Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32708516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.